Renal Cell Carcimona Cancer Drug Futures

Date: October 22, 2010
Price:
US$ 2,615.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R3AC1F884B0EN
Leaflet:

Download PDF Leaflet

Renal Cell Carcimona Cancer Drug Futures
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Renal Cell Carcinoma Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system

The number of renal cell carcinoma (RCC) patients....
....by value, in the US, Europe and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). Approximately 18% of the RCC patient population currently receives drug therapy but, by 2015, this percentage is expected to grow reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.

The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. Sales will be driven by the new targeted therapies which will account for sales of around US$6.1 billion in 2015,

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Renal Cell Carcinoma Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
  • Track the drug’s progress and stay abreast of developments
  • Understand the drug’s novelty and mode of action
  • Evaluate the strength of the company developing/producing the drug
  • Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
  • Know the launch timeframe for new products or indications
  • Be aware of promising mid-stage development candidates
  • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
  • Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
  • Novelty/rationale for mechanism of action
  • Current status
  • Proof of concept/clinical data
  • Development risks
  • Company expertise
  • Competition within the market-place
  • Sales forecast (for key late-stage and launched products)
  • Competitor ratio analysis score
  • Clinical trial results
OVER 35 RCC DRUGS INCLUDED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
  • Aldesleukin
  • Bevacizumab
  • Everolimus
  • Human lymphoblastoid interferon [IFN] alpha-N1
  • Interferon alpha-2a
  • Pazopanib
  • Sorafenib
  • Sunitinib malate
  • Temsirolimus
  • Vitespen
Phase III
  • Axitinib
  • Girentuximab
  • Naptumomab
  • Tivozanib
Phase II
  • AGS-003
  • AS1411
  • BIBF 1120
  • Foretinib
  • IMA901
  • Interleukin-21
  • L19
  • Linifanib
  • Panobinostat
  • Perifosine
  • Ramucirumab
  • Regorafenib
  • Talactoferrin alpha
Phase I/II
  • Dovitinib
  • IMP321
  • OncoVAX
Dicontinued/Suspended/Withdrawn
  • ABT-510
  • ABT-751
  • Archexin
  • SAR109659
  • IMO-2055
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

For further information on the products covered, discounts, distribution or a demonstration, please click on the link for Mark Hamson.

CANCER SECTORS COVERED IN THE DRUG FUTURE SERVICE
  • Breast
  • Lung
  • Colorectal
  • Renal Cell Carcinoma
  • Prostate
  • Blood (coming soon)
OVERVIEW

PHASE I

TREMELIMUMAB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise

PHASE I/II

DOVITINIB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise

IMP321

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ONCOVAX

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PHASE II

AGS-003


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

AS1411

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place

BIBF 1120

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

FORETINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

IMA901

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

INTERLEUKIN-21

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

L19

Mode of Action
Current Status

LINIFANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PANOBINOSTAT

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

PERIFOSINE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development/Commercialisation Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

RAMUCIRUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

REGORAFENIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

TALACTOFERRIN ALPHA

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

PHASE III

AXITINIB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

GIRENTUXIMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

NAPTUMOMAB ESTAFENATOX

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

TIVOZANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

APPROVED

ALDESLEUKIN


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

BEVACIZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

EVEROLIMUS

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

HUMAN LYMPHOBLASTOID INTERFERON [IFN] ALPHA-N1

INTERFERON ALPHA-2A


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development/Commercialisation Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PAZOPANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

SORAFENIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

SUNITINIB MALATE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

TEMSIROLIMUS

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

VITESPEN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

ABT-510

Mode of Action
Current Status
Clinical Trial Results

ABT-751

Mode of Action
Current Status

ARCHEXIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development/Commercialisation Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

IMO-2055

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Clinical Trial Results

SAR109659

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

METHODOLOGY
Skip to top


Breast Cancer Drug Futures US$ 2,615.00 Oct, 2010
Lung Cancer Drug Futures US$ 2,615.00 Oct, 2010
Colorectal Cancer Drug Futures US$ 2,615.00 Oct, 2010
Prostate Cancer Drug Futures US$ 2,615.00 Oct, 2010

Ask Your Question

Renal Cell Carcimona Cancer Drug Futures
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: